Expanding horizons of iminosugars as broad-spectrum anti-virals: mechanism, efficacy and novel developments
Authors:
Open Access
- 26 September 2024
- journal article
- review article
- Published by Springer Nature in Natural Products and Bioprospecting
- Vol. 14 (1) , 1-24
Abstract
Iminosugars, a class of polyhydroxylated cyclic alkaloids with intriguing properties, hold promising therapeutic potentials against a broad spectrum of enveloped viruses, including DENV, HCV, HIV, and influenza viruses. Mechanistically, iminosugars act as the competitive inhibitors of host endoplasmic reticular α-glucosidases I and II to disrupt the proper folding of viral nascent glycoproteins, which thereby exerts antiviral effects. Remarkably, the glycoproteins of many enveloped viruses are significantly more dependent on the calnexin pathway of the protein folding than most host glycoproteins. Therefore, extensive interests and efforts have been devoted to exploit iminosugars as broad-spectrum antiviral agents. This review provides the summary and insights into the recent advancements in the development of novel iminosugars as effective and selective antiviral agents against a variety of enveloped viruses, as well as the understandings of their antiviral mechanisms. Graphical AbstractKeywords
Funding Information
- National Key Research and Development Program of China (2023YFC2606500)
- National Natural Science Foundation of China (22377151)
- Key Research and Development Program of Hunan Province of China (2021WK2005)
- Hunan Provincial Science Fund for Distinguished Young Scholars (2023JJ10083)
- Huxiang high-level talent gathering project (2022RC4029)
This publication has 127 references indexed in Scilit:
- N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposureJournal of Virology, 1996
- N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120Journal of Virology, 1996
- The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 bindingJournal of Virology, 1995
- Inhibition of alpha-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoyl castanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cellsAntimicrobial Agents and Chemotherapy, 1994
- Effects of the imino sugar N-butyldeoxynojirimycin on the N-glycosylation of recombinant gp120.Journal of Biological Chemistry, 1993
- Distribution and Elimination of the Glycosidase Inhibitors 1-Deoxymannojirimycin and N-Methyl-1-Deoxynojirimycin in the Rat in VivoPharmaceutical Research, 1992
- 6–0-Butanoylcastanospermine (MDL 28,574) inhibits glycoprotein processing and the growth of HIVsAIDS, 1991
- PHARMACOKINETICS OF ACARBOSE .1. ABSORPTION, CONCENTRATION IN PLASMA, METABOLISM AND EXCRETION AFTER SINGLE ADMINISTRATION OF [C-14]ACARBOSE TO RATS, DOGS AND MAN1989
- Loss of cytomegalovirus infectivity after treatment with castanospermine or related plant alkaloids correlates with aberrant glycoprotein synthesisAntiviral Research, 1988
- Evaluation of the role of rat liver Golgi endo-alpha-D-mannosidase in processing N-linked oligosaccharides.Journal of Biological Chemistry, 1988